Yuji Oshima

Yuji Oshima

Auto-generated profile, based on publicly available information

Yuji Oshima

Section of Ophthalmology, Department of Medicine, Fukuoka Dental College, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2014 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
SNShunji Nakatake
Shunji Nakatake
SYShigeo Yoshida
Shigeo Yoshida
SNshintaro nakao
shintaro nakao
RARyoichi Arita
Ryoichi Arita
MYMiho Yasuda
Miho Yasuda
TITatsuro Ishibashi
Tatsuro Ishibashi
Several retinal ischemic diseases can cause neovascular glaucoma (NVG). Trabeculectomy with mitomycin C (MMC) is a relatively better treatment modality in the management of eyes with NVG than other glaucoma surgeries. The aim of this study was to investigate the factors that may influence the outcome of trabeculectomy with MMC for NVG.

29 March 2015 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
YOYuji Oshima
Yuji Oshima
RARajendra S Apte
Rajendra S Apte
SNshintaro nakao
shintaro nakao
SYShigeo Yoshida
Shigeo Yoshida
TITatsuro Ishibashi
Tatsuro Ishibashi
The pathogenesis of macular hole formation is widely accepted as a tractional force at the vitreo-retinal interface in fovea. We report a case of macular hole after intravitreous aflibercept injection for age-related macular degeneration (AMD) associated with contraction of the retinal pigment epithelium (RPE) at the edge of a fibrovascular pigment epithelial detachment (PED). A 94-year old man with neovascular AMD affecting his left eye accompanied by a fibrovascular PED was examined for severe vision loss. Although RPE tear in his left eye was identified before the first aflibercept intravitreous injection performed in order to treat neovascular AMD, he received three aflibercept injections as induction treatment. After induction treatment, a full thickness macular hole was identified associated with the contracted rolled RPE edge beneath the retina. Macular hole is commonly formed associated with tangential vitreous traction. Current report suggests that rapid contraction of the RPE underneath the retina can be one of the causes of a macular hole, and one of the side effects of anti-VEGF therapy for neovascular AMD.

22 May 2019 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
IWIori Wada
Iori Wada
YOYuji Oshima
Yuji Oshima
SSSatomi Shiose
Satomi Shiose
KKKumiko Kano
Kumiko Kano
SNShintaro Nakao
Shintaro Nakao
KSKoh-Hei Sonoda
Koh-Hei Sonoda

1 November 2011 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
EHEiichi Hasegawa
Eiichi Hasegawa
YOYuji Oshima
Yuji Oshima
ATAtsunobu Takeda
Atsunobu Takeda
KSKazuko Saeki
Kazuko Saeki
HYHiroki Yoshida
Hiroki Yoshida
TITatsuro Ishibashi
Tatsuro Ishibashi
AMD is the most common disease leading to acquired blindness in developed countries. CNV is the foremost cause of AMD and is thought to be induced by regional inflammation as a result of age-related conformational changes of the chorioretinal interface. Here, we show that IL-27, a member of the IL-6/IL-12 cytokine family, has an angiostatic effect and regulates the development of laser-induced experimental CNV in mice. In this model, IL-27 expression increased in the damaged choroid and peaked at the 24 h-time-point. IL-27 neutralization, induced by inoculating an antagonistic antibody into the vitreous cavity, enhanced VEGF production and the extent of CNV. By contrast, the administration of rIL-27 reduced VEGF production and the extent of CNV. Mice deficient in the EBI3, which lack IL-27, also showed more CNV than C57BL/6 mice, and this was reduced by IL-27 supplementation. We additionally investigated the effect of IL-27 on the function of macrophages, which play a critical role in CNV. IL-27 did not affect macrophage migration but inhibited its VEGF production. IL-27 therefore appears to regulate CNV and is a promising candidate target for treating sight-threatening diseases caused by ocular neovascularization.

21 November 2022 in Ophthalmology
Verified
Journal Article
Closed access
MAMasato Akiyama
Masato Akiyama
MMMasahiro Miyake
Masahiro Miyake
YMYukihide Momozawa
Yukihide Momozawa
SASatoshi Arakawa
Satoshi Arakawa
MMMaiko Maruyama-Inoue
Maiko Maruyama-Inoue
YKYoichiro Kamatani
Yoichiro Kamatani

23 January 2021 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
YOYuji Oshima
Yuji Oshima
YIYumi Ishibashi
Yumi Ishibashi
NUNaoyasu Umeda
Naoyasu Umeda
TNTatsuo Nagata
Tatsuo Nagata
SYShigeo Yoshida
Shigeo Yoshida
TITatsuro Ishibashi
Tatsuro Ishibashi
Background: To evaluate the correlation between visual acuity improvement and vision-related QOL after ranibizumab treatment in Japanese patients with AMD. Methods: In this one-year prospective, interventional, open-label, multicenter study involving four sites, patients with neovascular AMD were enrolled and observed for 12 months. Treatment-naïve patients received 0.5 mg ranibizumab as needed after three initial monthly doses. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at every visit. Evaluations with the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and patient satisfaction questionnaire were performed at baseline and 3 and 12 months after initial treatment. The primary endpoint was change in BCVA and QOL 3 months after ranibizumab treatment. QOL outcomes were also assessed in the better and poor BVCA subgroups. Results: The study enrolled 100 patients. The mean logMAR BCVA after treatment improved significantly from 0.43 to 0.30 at 3 months (p< 0.0001), and 0.28 at 12 months (p< 0.0001). The mean NEI-VFQ-25 composite scores improved from 79.48 to 84.13 at 3 months (p< 0.0001), and 86.0 at 12 months (p< 0.0001). The 3 and 12-month changes in NEI-VFQ-25 score and BCVA showed significant correlation. In the poor baseline visual acuity group (decimal BCVA ≤0.5), there was a significant correlation between the changes in the NEI-VFQ-25 score and BCVA (p=0.02) but not in the better baseline visual acuity group (decimal BCVA > 0.6, p=0.1) at 3 months. There were no significant differences in the satisfaction questionnaire score from baseline to at 3 months (p=0.54) and 12 months (p=0.23). The average CMT improved significantly from 340 to 264 μm at 3 months (p< 0.0001) and to 268 μm at 12 months (p< 0.0001). Conclusions: Intravitreal ranibizumab treatment resulted in improvement in visual acuity, anatomical change, and visual function change in Japanese AMD patients. Significant improvement was seen in patient visual function, and this was correlated with changes in VA, except immediately after loading dose treatment in patients with higher baseline VA. The patients’ satisfaction with the treatment remained unchanged during the study period. Trial registration: This study is registered at UMIN Clinical Trials Registry (UMIN000012013). Registered October 10, 2013, as prospective study.